贝伐珠单抗联合靶向治疗对EGFR突变型非小细胞肺癌患者的疗效观察

目的 探讨贝伐珠单抗联合靶向治疗对表皮生长因子受体(EGFR)突变型非小细胞肺癌(NSCLC)患者近远期预后及免疫状态、不良反应的影响,以期为临床治疗方法的选择提供参考.方法 选择2017年9月-2018年9月在浙江萧山医院和浙江省邵逸夫医院接受诊治的EGFR突变型NSCLC患者80例,按照随机数字表法分为对照组和观察...

Observation of curative effect of bevacizumab combined with targeted treatment of EGFR mutant lung cancer

  Objective  To investigate the effect of bevacizumab combined with targeted therapy on the short- and long-term prognosis, immune status, and side effects of patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), in order to provide reference for the choice of clinical treatment.   Methods   A total of 80 EGFR-mutant NSCLC patients who were diagnosed and treated in our hospital from September 2017 to September 2018 were selected and divided into control group and observation group according to the random number table method, with 40 cases in each group. The control group was treated with icotinib hydrochloride tablets, and the observation group was treated with bevacizumab combined with icotinib hydrochloride tablets. The clinical efficacy, tumor marker levels, and immune index levels were compared between the two groups of patients, and the survival and toxicity of the two groups were compared.   Results   The disease control rate (DCR) of the observation group was significantly higher than that of the control group (P < 0.05). After treatment, the levels of vascular endothelial growth factor (VEGF), carbohydrate antigen 125 (CA125), and cytokeratin 19 fragment (CYFRA21-1) in the two groups were significantly lower than those before treatment, and the observation group were significantly lower than those in the control group (P < 0.05). After treatment, the levels of CD3+, CD4+/CD8+ in the two groups were significantly higher than those before treatment, and the observation group were significantly higher than those in the control group (P < 0.05). The survival of patients in the observation group was better than that of the control group (P < 0.05). The total incidence of side effects in the observation group was significantly lower than that in the control group (P < 0.05).   Conclusion   Bevacizumab combined with icotinib hydrochloride in the treatment of EGFR mutant NSCLC patients has a significant effect, which can effectively inhibit the proliferation of tumor cells, reduce the tumor volume, improve the body's immune function, and improve the survival rate of patients.